Since 2010 ASCO update the guidelines, this update reflects 5 of tamoxifen maintenance treatment on the new data have been considered. Have
Since 2010 ASCO update the guidelines, this update reflects 5 of tamoxifen maintenance treatment on the new data have been considered. Have in the two largest randomized study the longest follow-up period, compared with patients who received only 5 years of tamoxifen treatment, patients receiving tamoxifen therapy for 10 years showed a survival advantage of breast cancer, and breast cancer recurrence and contralateral breast cancer risk.
"Will receive tamoxifen therapy for 5 years as a standard adjuvant endocrine therapy, has been for decades, but now we have evidence to suggest that for hormone receptor positive breast cancer in women 10 years of tamoxifen treatment," Professor J.Burstein Harold (Chairman of the joint ASCO expert group drafted the guidelines of the said). "Postmenopausal women also have a choice of an aromatase inhibitor tamoxifen as an alternative or turn in after tamoxifen. Aromatase inhibitors are not recommended for premenopausal women."
Hormone receptor positive (HR+) breast cancer is the most common type of breast cancer worldwide. About 60% to 75% of women with breast cancer are estrogen receptor positive (ER+) breast cancer, and about 65% of these cancers are also positive for progesterone receptor (PgR+). Adjuvant endocrine therapy is very effective for almost all ER- positive and / or PgR- positive tumors in women.
In order to determine the clinical practice guidelines, the ASCO team conducted a systematic review of the relevant medical literature. Two on the extension of tamoxifen maintain time -- a randomized trial published another article, at the ASCO annual meeting in 2013 to submit for the new recommendations provided evidence. Since the last edition of the guidelines update, no new evidence on the extension of the duration of aromatase inhibitors.